← Back to Clinical Trials
Recruiting NCT06624930

NCT06624930 Behaviour Change for Cancer Survivors Trial

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06624930
Status Recruiting
Phase
Sponsor University of Toronto
Condition Cancer
Study Type INTERVENTIONAL
Enrollment 236 participants
Start Date 2024-10-03
Primary Completion 2028-05-31

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type INTERVENTIONAL
All Conditions
Interventions
Behavioural CounsellingExercise Counselling

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 236 participants in total. It began in 2024-10-03 with a primary completion date of 2028-05-31.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

This study will be a two-arm RCT, to examine the effects of an entirely virtual, 6-month supervised PA program plus standard exercise counselling (PA+EC) versus a supervised PA plus motivationally-enhanced behavioral counselling (PA+BC) on moderate to vigorous physical activity (MVPA) in cancer survivors. A 6-month post intervention follow-up (T2) and 1-year post intervention follow-up (T3; 1-year follow-up from post-intervention) will take place after the intervention to address maintenance. The intervention is designed using evidence-based research in the fields of exercise oncology using effective clinical design and theoretical approaches, including behaviour change techniques, to gradually increase MVPA to at least 90 minutes per week in cancer survivors as per the exercise guidelines for cancer survivors.

Eligibility Criteria

Inclusion Criteria: * ≥18 years of age * Confirmed diagnosis of cancer of any type (Stages I to III; localized) * Have completed primary cancer treatment within 5 years * At least 12 weeks after surgery completion * At least 6 weeks after radiation treatment * Proficient in English * Physically inactive (self-report less than 90 min of MVPA/week ) * Ambulate in daily life with minimal gait aid use * Access to a smartphone/tablet/computer with webcam for videoconferencing and a Bluetooth connection * Access to the internet * No cardiac contraindications (e.g., unstable angina, heart failure, coronary artery disease, diagnosed abnormality of heart rhythm) Exclusion Criteria: * A medical condition that prohibits PA (e.g., joint restriction or weight bearing precautions) * Uncontrolled comorbidities or cardiovascular contraindications that would increase risk associated with supervised and unsupervised exercise (e.g., cardiac contraindications, severe arthritis, recent fall within the last 6-12 months) * Presence of advanced cancer (i.e., Stage IV; metastatic) * Pregnancy * Do not intend to live in Canada for the next 18 months

Contact & Investigator

Central Contact

Linda Trinh, PhD

✉ exercise.oncology@utoronto.ca

📞 4169463624

Principal Investigator

Linda Trinh, PhD

PRINCIPAL INVESTIGATOR

University of Toronto

Frequently Asked Questions

Who can join the NCT06624930 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06624930 currently recruiting?

Yes, NCT06624930 is actively recruiting participants. Contact the research team at exercise.oncology@utoronto.ca for enrollment information.

Where is the NCT06624930 trial being conducted?

This trial is being conducted at Toronto, Canada.

Who is sponsoring the NCT06624930 clinical trial?

NCT06624930 is sponsored by University of Toronto. The principal investigator is Linda Trinh, PhD at University of Toronto. The trial plans to enroll 236 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology